Synergistic antibacterial activity of norfloxacin and sulfadiazine against planktonic and biofilm-forming multidrug-resistant Escherichia coli strain
FEMS Microbiology Letters · 07.01.2026 · 373
DOI: 10.1093/femsle/fnag054 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEMS Microbiology Letters, online erschienen am 30.04.2026. Verfasst von Rosalía Ayala Gómez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Farmacia, Centro Regional de Investigación y Desarrollo Científico Tecnológico (CRIDECIT), Universidad Nacional de la Patagonia San J…. Hauptthemen laut MEDLINE: Norfloxacin, Biofilms, Escherichia coli, Sulfadiazine. Die Arbeit nennt 85 Literaturangaben. Gefördert von: Secretaria de Ciencia y Tecnología - Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas.
Abstract (Originalsprache)
Antimicrobial resistance represents a major global health concern, particularly in countries where multidrug-resistant (MDR) pathogens are widespread. Biofilm formation further complicates therapeutic strategies. This study investigated the synergistic effects of combining norfloxacin (NOR) and sulfadiazine (SDZ) against three Escherichia coli strains: a reference, a quinolone-resistant clinical isolate, and a highly resistant extended-spectrum β-lactamase (ESBL)-producing strain. Checkerboard assays and isobolograms revealed synergistic or partially synergistic effects across all strains, with Fractional Inhibitory Concentration Index (FICI) values ranging from 0.37 to 1.0. Notably, the ESBL strain displayed enhanced synergy (FICI = 0.75) under white LED light irradiation. Reactive oxygen species (ROS) analysis showed that SDZ generated higher levels than NOR, particularly in the quinolone-resistant clinical isolate, while the NOR–SDZ combination yielded lower levels. Scanning electron microscopy of biofilms confirmed that the drug combination caused greater structural disruption than either monotherapy, especially at NOR (FIC × 100) and SDZ (FIC × 10). Subinhibitory monotherapies modulated the biofilm phenotype, underscoring the benefits of combined treatments. Overall, these findings highlight the NOR–SDZ combination as a promising therapeutic approach against MDR E. coli, where drug synergy and biofilm disruption emerge as key strategies to combat antimicrobial resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Farmacia, Centro Regional de Investigación y Desarrollo Científico Tecnológico (CRIDECIT), Universidad Nacional de la Patagonia San Juan Bosco, Comodoro Rivadavia 9000, Argentina.
- Departamento de Ciencias Farmacéuticas, Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA-CONICET), Universidad Nacional de Córdoba, Córdoba 5000, Argentina.
Förderung
- Secretaria de Ciencia y Tecnología - Universidad Nacional de Córdoba
- Consejo Nacional de Investigaciones Científicas y Técnicas
Zitieren
APA
Gómez, R. A., Silvero C, M. J., Becerra, M. C., & Pinto Vitorino, G. (2026). Synergistic antibacterial activity of norfloxacin and sulfadiazine against planktonic and biofilm-forming multidrug-resistant Escherichia coli strain. FEMS Microbiology Letters, 373. https://doi.org/10.1093/femsle/fnag054
Vancouver
Gómez RA, Silvero C MJ, Becerra MC, Pinto Vitorino G. Synergistic antibacterial activity of norfloxacin and sulfadiazine against planktonic and biofilm-forming multidrug-resistant Escherichia coli strain. FEMS Microbiology Letters. 2026;373. doi:10.1093/femsle/fnag054
BibTeX
@article{Gmez2026,
author = {Gómez, Rosalía Ayala and Silvero C, María Jazmín and Becerra, María Cecilia and Pinto Vitorino, Graciela},
title = {Synergistic antibacterial activity of norfloxacin and sulfadiazine against planktonic and biofilm-forming multidrug-resistant Escherichia coli strain},
journal = {FEMS Microbiology Letters},
year = {2026},
volume = {373},
doi = {10.1093/femsle/fnag054}
}
EUVIMED